Evidence map›Paper›PMID 41853117›Full record

ArticleASM case reports2026

J A M C Dirks, L Mulder, K Burgers, J G M C Damoiseaux, E R Heddema

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in ASM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Antimicrobial Management of SevereInfection and drug resistance · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

J A M C DirksDepartment of Medical Microbiology (and reference laboratory for human Chlamydia infections from animal origin), Zuyderland Medical Center, Sittard-Geleen, the Netherlands.ORCID https://orcid.org/0000-0002-1961-9589
L MulderPulmonology Department, Zuyderland Medical Center, Heerlen, the Netherlands.
K BurgersDepartment of Sexual Health, Infectious Diseases and Environmental Health, Public Health Service South Limburg, Heerlen, the Netherlands.
J G M C DamoiseauxDepartment of Medical Microbiology (and reference laboratory for human Chlamydia infections from animal origin), Zuyderland Medical Center, Sittard-Geleen, the Netherlands.ORCID https://orcid.org/0000-0003-4007-6985
E R HeddemaDepartment of Medical Microbiology (and reference laboratory for human Chlamydia infections from animal origin), Zuyderland Medical Center, Sittard-Geleen, the Netherlands.ORCID https://orcid.org/0000-0001-5199-4226

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ustekinumab, a monoclonal antibody targeting the p40 subunit of interleukin-12 and interleukin-23, is widely used for immune-mediated diseases such as Crohn's disease. By modulating Th1 and Th17 pathways, ustekinumab may increase susceptibility to intracellular pathogens. We report the first case of Case Summary: A 27-year-old woman with Crohn's disease presented with severe community-acquired pneumonia, progressive hypoxemia, and pulmonary embolism 3 weeks after initiating ustekinumab therapy. Despite broad-spectrum antibiotics, clinical improvement was limited. Her exposure history revealed contact with multiple pet birds, several of which died recently. Polymerase chain reaction testing confirmed Conclusion: This case highlights a potential association between ustekinumab and susceptibility to

Indexed as

biologic therapyChlamydia psittaciopportunistic infectionustekinumab

Identifiers

PMID41853117
PMCPMC12955446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.